NASDAQ:BEAM

Beam Therapeutics Competitors

$68.82
-1.41 (-2.01 %)
(As of 04/12/2021 12:00 AM ET)
Add
Compare
Today's Range
$66.27
Now: $68.82
$70.32
50-Day Range
$70.23
MA: $85.43
$110.41
52-Week Range
$14.80
Now: $68.82
$126.90
Volume1.40 million shs
Average Volume1.11 million shs
Market Capitalization$4.30 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Beam Therapeutics (NASDAQ:BEAM) Vs. TECH, ARGX, NVAX, QGEN, RGEN, and NBIX

Should you be buying BEAM stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Beam Therapeutics, including Bio-Techne (TECH), argenx (ARGX), Novavax (NVAX), QIAGEN (QGEN), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

Bio-Techne (NASDAQ:TECH) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Bio-Techne and Beam Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Techne$738.69 million21.17$229.30 million$3.86104.42
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90

Bio-Techne has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bio-Techne and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bio-Techne32.69%12.20%8.09%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional & Insider Ownership

93.8% of Bio-Techne shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Bio-Techne shares are owned by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Bio-Techne and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bio-Techne03702.70
Beam Therapeutics03302.50

Bio-Techne currently has a consensus target price of $367.50, suggesting a potential downside of 8.82%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Bio-Techne.

Summary

Bio-Techne beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.

argenx (NASDAQ:ARGX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares argenx and Beam Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenx$78.17 million172.78$-182,520,000.00($4.73)-55.66
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90

Beam Therapeutics has lower revenue, but higher earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares argenx and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
argenxN/AN/AN/A
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional & Insider Ownership

54.2% of argenx shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for argenx and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
argenx071002.59
Beam Therapeutics03302.50

argenx currently has a consensus target price of $293.1875, suggesting a potential upside of 11.37%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than argenx.

Summary

argenx beats Beam Therapeutics on 8 of the 13 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Earnings and Valuation

This table compares Novavax and Beam Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million695.25$-132,690,000.00($5.80)-30.28
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90

Beam Therapeutics has lower revenue, but higher earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novavax and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional & Insider Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 3.3% of Novavax shares are owned by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Novavax and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax10602.71
Beam Therapeutics03302.50

Novavax currently has a consensus target price of $229.6429, suggesting a potential upside of 30.74%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Novavax.

Summary

Novavax beats Beam Therapeutics on 8 of the 13 factors compared between the two stocks.

QIAGEN (NYSE:QGEN) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Profitability

This table compares QIAGEN and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
QIAGEN11.18%17.51%8.44%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Institutional & Insider Ownership

43.6% of QIAGEN shares are owned by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are owned by institutional investors. 9.0% of QIAGEN shares are owned by company insiders. Comparatively, 0.7% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for QIAGEN and Beam Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
QIAGEN05902.64
Beam Therapeutics03302.50

QIAGEN currently has a consensus target price of $60.76, suggesting a potential upside of 17.80%. Beam Therapeutics has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Given Beam Therapeutics' higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than QIAGEN.

Earnings and Valuation

This table compares QIAGEN and Beam Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QIAGEN$1.53 billion7.70$-41,460,000.00$1.4336.07
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90

QIAGEN has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Summary

QIAGEN beats Beam Therapeutics on 10 of the 13 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Beam Therapeutics and Repligen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
Repligen13.40%6.58%5.00%

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 84.3% of Repligen shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 1.7% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Beam Therapeutics and Repligen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Repligen00503.00

Beam Therapeutics presently has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Repligen has a consensus target price of $219.00, suggesting a potential upside of 5.79%. Given Beam Therapeutics' higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Repligen.

Valuation and Earnings

This table compares Beam Therapeutics and Repligen's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90
Repligen$270.24 million41.96$21.41 million$1.07193.48

Repligen has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Summary

Repligen beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.

Beam Therapeutics (NASDAQ:BEAM) and Neurocrine Biosciences (NASDAQ:NBIX) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Profitability

This table compares Beam Therapeutics and Neurocrine Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Beam Therapeutics-529,075.00%-103.41%-48.05%
Neurocrine Biosciences8.96%18.18%9.50%

Institutional and Insider Ownership

49.8% of Beam Therapeutics shares are held by institutional investors. Comparatively, 95.3% of Neurocrine Biosciences shares are held by institutional investors. 0.7% of Beam Therapeutics shares are held by company insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Beam Therapeutics and Neurocrine Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Beam Therapeutics03302.50
Neurocrine Biosciences081202.60

Beam Therapeutics presently has a consensus target price of $96.00, suggesting a potential upside of 39.49%. Neurocrine Biosciences has a consensus target price of $128.7222, suggesting a potential upside of 38.72%. Given Beam Therapeutics' higher probable upside, equities research analysts plainly believe Beam Therapeutics is more favorable than Neurocrine Biosciences.

Valuation and Earnings

This table compares Beam Therapeutics and Neurocrine Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beam Therapeutics$20,000.00214,959.27$-78,330,000.00($14.05)-4.90
Neurocrine Biosciences$788.10 million11.06$37.01 million$0.39237.92

Neurocrine Biosciences has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Neurocrine Biosciences beats Beam Therapeutics on 11 of the 13 factors compared between the two stocks.


Beam Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
2.0$403.05-1.4%$15.64 billion$738.69 million64.49
argenx logo
ARGX
argenx
1.3$263.25-5.6%$13.51 billion$78.17 million-55.66Analyst Upgrade
Novavax logo
NVAX
Novavax
1.6$175.65-2.3%$12.97 billion$18.66 million-33.65
QIAGEN logo
QGEN
QIAGEN
1.5$51.58-0.6%$11.76 billion$1.53 billion63.68Analyst Downgrade
Repligen logo
RGEN
Repligen
1.5$207.02-0.4%$11.34 billion$270.24 million252.46Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$92.79-0.6%$8.72 billion$788.10 million99.78Analyst Downgrade
News Coverage
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$114.39-1.2%$8.63 billion$289.59 million-35.09
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$123.08-3.1%$7.45 billion$73.99 million-47.52
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$75.00-4.0%$7.03 billion$10.68 million-40.76Analyst Revision
Twist Bioscience logo
TWST
Twist Bioscience
1.2$129.01-2.5%$6.28 billion$90.10 million-34.40Analyst Report
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$42.95-0.4%$6.15 billion$195.99 million268.44
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$50.30-3.9%$6.09 billion$26.68 million-22.76News Coverage
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$40.17-0.6%$5.59 billion$85.07 million-42.28Insider Selling
Vir Biotechnology logo
VIR
Vir Biotechnology
1.7$43.12-0.0%$5.52 billion$8.09 million-18.27Gap Down
Kodiak Sciences logo
KOD
Kodiak Sciences
1.5$106.20-2.7%$5.43 billionN/A-45.78
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.52-0.4%$4.66 billion$503.70 million33.11
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$29.41-2.7%$4.32 billionN/A-15.32News Coverage
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$29.58-11.0%$4.16 billionN/A-13.89Analyst Report
News Coverage
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$67.45-2.2%$3.30 billionN/A-38.76
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$69.04-1.9%$3.08 billion$125.57 million-40.37
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.77-2.6%$2.96 billionN/A0.00
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$39.25-8.7%$2.88 billion$50.04 million0.00Insider Selling
News Coverage
Vericel logo
VCEL
Vericel
1.1$58.18-0.7%$2.68 billion$117.85 million-5,818,000.00
Editas Medicine logo
EDIT
Editas Medicine
1.6$39.51-0.1%$2.66 billion$20.53 million-22.71Gap Down
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.94-8.2%$1.95 billion$31.43 million-4.75News Coverage
bluebird bio logo
BLUE
bluebird bio
1.8$27.98-0.6%$1.88 billion$44.67 million-2.55
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$22.26-7.3%$1.81 billionN/A-10.40
NantKwest logo
NK
NantKwest
1.3$16.09-4.8%$1.76 billion$40,000.00-22.66
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.7$9.50-7.5%$1.69 billion$48.83 million-12.50
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.06-0.4%$1.59 billion$102.43 million-18.43Analyst Upgrade
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$71.03-2.4%$1.58 billionN/A-47.99News Coverage
Immunovant logo
IMVT
Immunovant
1.8$15.27-2.7%$1.50 billionN/A-11.84
AlloVir logo
ALVR
AlloVir
1.4$22.76-2.0%$1.48 billionN/A0.00
REGENXBIO logo
RGNX
REGENXBIO
1.6$33.75-4.2%$1.43 billion$35.23 million-13.61
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$31.43-6.4%$1.41 billionN/A0.00Insider Selling
Replimune Group logo
REPL
Replimune Group
1.5$29.35-2.5%$1.36 billionN/A-16.58News Coverage
Alector logo
ALEC
Alector
1.3$16.80-3.4%$1.34 billion$21.22 million-7.53
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$30.71-6.3%$1.32 billionN/A0.00News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$17.12-0.8%$1.29 billion$7.80 million-16.00
Ocugen logo
OCGN
Ocugen
1.1$6.68-4.2%$1.26 billionN/A-4.51
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.70-0.5%$1.15 billionN/A-2.97
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.29-2.2%$1.12 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.45-0.7%$1.10 billion$32.16 million-9.60
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.16-0.3%$1.03 billionN/A0.00
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.70-1.8%$997.28 million$356.07 million6.72
Curis logo
CRIS
Curis
1.3$10.82-6.3%$990.24 million$10 million-13.20
Scholar Rock logo
SRRK
Scholar Rock
1.5$27.84-7.5%$953.88 million$20.49 million-11.55
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$25.00-15.2%$944.03 millionN/A0.00Analyst Report
News Coverage
Gap Down
Cortexyme logo
CRTX
Cortexyme
1.3$31.88-5.4%$942.12 millionN/A-13.28
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.75-0.5%$894.42 millionN/A-4.09High Trading Volume
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.